Clinical Trial

Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-20; most recent amendment 2023-06-13.
Trial Details
NCT Number NCT05432739
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners West London Cancer Alliance, Imperial College London, University College London Hospitals, Lewisham and Greenwich NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, King's College Hospital NHS Trust, University College London (UCL) Cancer Institute, Institute of Cancer Research, United Kingdom, Francis Crick Institute, Royal Sussex County Hospital
Conditions Lung Cancer
Enrollment 500 participants
Start Date 2021-04-07
Primary Completion 2026-01-01 (estimated)
Study Completion 2031-01-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-15